Saba Capital Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Saba Capital Management’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-965,348	Closed	-$9.75M	–	966
2022 Q4	$9.75M	Hold	965,348	–	–	0.13%	266
2022 Q3	$9.58M	Buy	965,348 +60,405	+7%	+$597K	0.11%	351
2022 Q2	$8.96M	Hold	904,943	–	–	0.1%	364
2022 Q1	$8.92M	Hold	904,943	–	–	0.13%	277
2021 Q4	$8.9M	Hold	904,943	–	–	0.13%	221
2021 Q3	$8.81M	Buy	904,943 +315,057	+53%	+$3.05M	0.22%	118
2021 Q2	$5.7M	Buy	+589,886	New	+$5.73M	0.16%	139

Saba Capital Management's BIOT Position: Q1 2023 in Review

Saba Capital Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 965,348 shares — an estimated $9.75M sold.

Saba Capital Management first reported a position in BIOT in Q2 2021 and held it in 7 quarters. The position peaked at $9.75M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Saba Capital Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Saba Capital Management sold 965,348 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $9.75M.
Saba Capital Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Saba Capital Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $9.75M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Saba Capital Management's 13F filing for Q1 2023, filed 15 May 2023.